Cytokinetics (CYTK) EBIAT (2016 - 2025)
Cytokinetics (CYTK) has disclosed EBIAT for 16 consecutive years, with -$345.4 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT changed N/A to -$345.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$947.4 million, a N/A change, with the full-year FY2025 number at -$785.0 million, down 33.15% from a year prior.
- EBIAT was -$345.4 million for Q4 2025 at Cytokinetics, down from -$306.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$19.8 million in Q2 2022 to a low of -$345.4 million in Q4 2025.
- A 5-year average of -$132.5 million and a median of -$134.4 million in 2025 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 2296.41% in 2021, then surged 67.8% in 2022.
- Cytokinetics' EBIAT stood at -$30.6 million in 2021, then plummeted by 349.39% to -$137.4 million in 2022, then grew by 0.35% to -$136.9 million in 2023, then dropped by 17.28% to -$160.5 million in 2024, then crashed by 115.17% to -$345.4 million in 2025.
- Per Business Quant, the three most recent readings for CYTK's EBIAT are -$345.4 million (Q4 2025), -$306.2 million (Q3 2025), and -$134.4 million (Q2 2025).